An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma



Status:Archived
Conditions:Skin Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:June 2010
End Date:June 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

An Open-Label, Dose-Escalation Phase 1/1b Study of the Anti-gp75 Monoclonal Antibody IMC-20D7S In Patients With Malignant Melanoma Who Have Progressed After or During at Least One Treatment With Standard Cytotoxic Treatment or/and Immunotherapy Therapy or For Whom Standard Therapy is Not Indicated


A dose escalation study designed to determine the safety, maximum tolerated dose,
anti-melanoma activity, antibody blood levels and progression-free survival in patients with
malignant melanoma receiving IMC-20D7S either every two weeks or every three weeks.



We found this trial at
2
sites
ImClone Investigational Site
Burlington, Massachusetts 01805
?
mi
from
Burlington, MA
Click here to add this to my saved trials
West Virginia University Hospitals Inc.
1 Medical Center Drive
Morgantown, West Virginia 26506
304-598-4800
West Virginia University Hospitals Inc. WVU Healthcare is two corporations, University Health Associates and WVU...
?
mi
from
Morgantown, WV
Click here to add this to my saved trials